NCT05558761View on ClinicalTrials.gov

Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

April 20, 2024

Study Completion Date

April 20, 2024

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

Pentoxifylline 400 MG

Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics. PTX exerts anti-inflammatory effects by inhibiting phosphodiesterase and activating the adenosine 2 receptor

Trial Locations (1)

35511

Faculty of Medicine, Mansoura University, Al Mansurah

All Listed Sponsors
lead

Tanta University

OTHER